Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib in IDH1-mutated Chondrosarcoma
NCT06127407Phase 3Recruiting
- Sponsor
- Servier
- Start
- Jul 2024
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of ivosidenib in chondrosarcoma, sponsored by Servier. Started Jul 2024; status: recruiting.
02
Drugs
ivosidenib
03
Conditions
chondrosarcoma
Beyond the preview
Go deeper on NCT06127407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06127407.